GleamWall
中文EN

RVRC Revium Rx.

Pharmaceutical Preparations · OTC · SEC CIK 1839140 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets22.4%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312025Q22025-06-302025Q12025-03-31
Income statement
Revenue————
R&D expense$443,000$473,000$391,000$218,000
SG&A expense$289,000$266,000$547,000$519,000
Operating income-$732,000-$739,000-$938,000-$737,000
Net income-$748,000-$725,000-$1.04M-$634,000
EBITDA-$732,000-$737,000——
EPS (basic)0.010.010.020.01
EPS (diluted)0.010.010.020.01
Weighted avg. shares (diluted)60.73M60.73M60.73M60.73M
Balance sheet
Cash & equivalents$842,000$920,000$3.65M$3.91M
Current assets$1.86M$2.48M——
PP&E, net$9,000$9,000——
Goodwill$2.58M$2.58M——
Intangibles$2.50M$2.50M——
Total assets$7.11M$7.75M——
Current liabilities$971,000$1.53M——
Total liabilities$1.59M$1.60M——
Shareholders' equity$5.52M$6.16M$18.53M$19.41M
Shares outstanding60.73M60.73M——
Cash flow statement
Operating cash flow-$626,000-$541,000-$759,000-$357,000
Investing cash flow$548,000-$217,000$496,000$1.00M
Depreciation & amortization$0$2,000——
Stock-based compensation$111,000—$154,000$340,000

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.